

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 2003/084941 A3

(51) International Patent Classification⁷: C07D 295/18,
241/24, 211/60, 207/16, A61K 31/40, 31/44, 31/535,
A61P 29/00

Basel (CH). NEUMANN, Ulf [DE/CH]; Waldhofstrasse
62, CH-4310 Rheinfelden (CH).

(21) International Application Number:
PCT/EP2003/003644

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellec-
tual Property, CH-4002 Basel (CH).

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,
TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(30) Priority Data:
0208176.8 9 April 2002 (09.04.2002) GB

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): NO-
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

Published:

— with international search report

(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).


(88) Date of publication of the international search report:
25 March 2004

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): JANSER, Philipp
[CH/CH]; Delsbergerallee 1, CH-4053 Basel (CH).
MILTZ, Wolfgang [DE/CH]; Tessinstrasse 12, CH-4054

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: HYDROXAMIC ACID DERIVATIVES



(57) Abstract: Novel hydroxamic acid derivatives, e.g.,
of formula (I), wherein R₁, R₂, R₃ and R₄ are as defined,
are found to be useful as pharmaceuticals, e.g., for the
suppression of TNF release and the treatment of autoim-
mune and inflammatory diseases, e.g., multiple sclerosis
and rheumatoid arthritis. Methods of making the com-
pounds, novel intermediates, and pharmaceutical com-
positions comprising the compounds are provided.